Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 4/20 | 0.41 |
| ▸ | OXTR | P30559 | 10/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20678653 | 1.00 | GRM7 (0.41) | GRM7OXTRCYP3A4AVPR2AVPR1A | |
| SCHEMBL19200422 | 1.00 | GRM7 (0.41) | GRM7OXTRCYP3A4AVPR2AVPR1A | |
| SCHEMBL20678727 | 0.87 | GRM7 (0.50) | GRM7OXTRAVPR2CYP2D6 | |
| SCHEMBL19200403 | 0.87 | GRM7 (0.50) | GRM7OXTRAVPR2CYP2D6 | |
| SCHEMBL19182809 | 0.87 | GRM7 (0.50) | GRM7OXTRAVPR2CYP2D6 | |
| SCHEMBL19200271 | 0.86 | GRM7 (0.41) | GRM7OXTRCYP3A4AVPR2AVPR1A | |
| SCHEMBL19200400 | 0.86 | GRM7 (0.41) | GRM7OXTRCYP3A4AVPR2AVPR1A | |
| SCHEMBL20678740 | 0.86 | GRM7 (0.50) | GRM7OXTRCYP3A4AVPR2AVPR1A | |
| SCHEMBL19200937 | 0.86 | GRM7 (0.50) | GRM7OXTRCYP3A4AVPR2AVPR1A | |
| SCHEMBL20678739 | 0.86 | GRM7 (0.50) | GRM7OXTRCYP3A4AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | claimed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | GRM7 1/4885OXTR 248/4885CYP3A4 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.